Contents

Search

nadofaragene firadenovec

No yet FDA-approved. Indications: - intravesicular treatmentof bladder cancer resistant to BCG Dosage: - intravesicular administration every 3 months Mechanism of action: - adenovirus vector-based gene therapy containing the interferon alfa-2b gene - adenovirus enters cells of the bladder wall, the gene is transcribed, & the cells then secrete interferon alfa-2b protein [1] - response maintained at 12 months in 45% of patients

General

antineoplastic agent (chemotherapeutic agent)

References

  1. Worcester S Novel Gene Therapy Wows for BCG-Unresponsive Bladder Cancer. Medscape - Dec 08, 2020. https://www.medscape.com/viewarticle/942184